A Prospective Study of Application of Platelet Mapping in HBV-related Acute-on-chronic-liver Failure in China
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Ineffective hemostasis or a paradoxical prothrombotic state of Acute-on-chronic liver disease (ACLF) has been well established. Thrombelastography measures the dynamics of thrombin production and provides a global assessment of coagulation incorporating the cumulative effect of the interactions at various levels between plasma components and cellular component of coagulation. And through the platelet mapping, it can help provide a picture of patients' function of platelet. This study aims to explore the predictive role of platelet mapping in ACLF prognosis, organ failure developments and short term mortality.
Condition or disease
Thrombelastography,Acute on Chronic Liver Failure, Platelet
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with HBV-related chronic liver disease, International Normalized Ratio (INR)≥1.5 and total bilirubin≥85μmol/L
patient with previously diagnosed or undiagnosed HBV related chronic liver disease/cirrhosis
INR≥1.5 and total bilirubin≥85μmol/L
INR≤1.5 or total bilirubin≤85μmol/L;
underlying chronic liver disease was other than chronic HBV infection related;
those who had hepatocellular carcinoma or other types of malignancies;
obstructive biliary diseases or other disease lead to bilirubin evaluation;
those who had acute hemorrhage one week before admission
those who received platelet, cryo transfusion or plasmapheresis one week before admission
using steroid or immunosuppressant or antiplatelet or anticoagulant drugs in 4 weeks
any kind of decompensation which persisted over a month
pregnancy and breastfeeding
those who received liver transplantation or kidney transplantation;
combine with other disease lead to organ failure including heart failure (NYHA IV),respiratory failure（PaO2<60mmHg),renal insufficiency(CKD 5) and conscious disturbance (GCS<8)